In large obesity trials using full doses, once-weekly semaglutide and tirzepatide led to substantial average weight loss and improved metabolic markers in adults with obesity.[13] For example, the STEP 1 trial of once-weekly semaglutide in adults with overweight or obesity and the SURMOUNT-1 tirzepatide obesity trial both showed strong weight-loss effects when combined with lifestyle changes
On 29 January 2026, the MHRA updated product information for GLP-1s and issued a drug safety alert to highlight that acute pancreatitis is a known but infrequent side effect that can be fatal, stressing that patients and clinicians should be alert to initial symptoms, such as severe, persistent stomach pain that may radiate to the back and may be accompanied by nausea and vomiting 26
Last week, Novo Nordisk announced results from another clinical trial that found that Ozempic slowed the progression of kidney disease in patients with Type 2 diabetes
HPLC chromatogram and ESI-MS identity confirmation included on every COA
While this is the main target population, there are circumstances where people with a BMI under 27 may stand to benefit from Semaglutide GLP-1 under stringent medical supervision
I wish the weight loss meds could be more affordable Experience was seamless and very happy with the product It does really help with appetite
